AN2 Therapeutics, Inc. (ANTX): Total Assets
$61.95M
As of 2025-12-31
$81.68M
As of 2026-06-30
-15.5%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.95M | -32.7% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $92.09M | -33.6% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $138.74M | +35.3% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $102.56M | +57.0% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $65.32M | n/a | 2023-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $61.95M | -32.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $62.12M | -45.9% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
| Rallybio Corp (RLYB) | 2025-12-31 | $62.26M | -8.6% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $61.37M | +32.4% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $60.24M | +275.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $59.87M | -5.3% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $59.56M | -32.5% |
Compare ANTX, LFVN, OKUR, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗